Navigation Links
Halozyme Therapeutics Reports Third Quarter 2011 Financial Results
Date:11/7/2011

a study in type 1 diabetes patients who receive their insulin treatment via pump. The study demonstrated that pre-administration of rHuPH20 led to consistent insulin exposure over the infusion set life and better glucose control following meals.
  • Reported results from two Phase 2 clinical trials of its ultrafast rHuPH20 insulin analog formulations in patients with Type 1 and Type 2 diabetes. Both trials met the primary endpoint of non-inferiority of HbA1C compared to insulin analog. rHuPH20 insulin analog use resulted in a greater than 50% increase in the proportion of patients able to consistently (i.e. during at least 2/3 of meals) achieve AACE (American Association of Clinical Endocrinologists) guidelines for post-prandial glucose targets at both one and two hours after meals in both Type 1 and Type 2 patients.
  • Initiated a Phase 2 study with PEGPH20 in patients with stage IV previously untreated pancreatic cancer.
  • Initiated a Phase 1/2 study with HTI-501 in women with moderate to severe edematous fibrosclerotic panniculopathy, or cellulite.
  • Baxter presented its Phase III data for the HyQ program at the American College of Allergy, Asthma & Immunology.  HyQ was shown to be effective in subjects with Primary Immunodeficiency and enabled 94% of subjects to receive full 3 or 4-weekly doses of IgG using a single site with very good local and systemic tolerability.  Systemic infusion reactions occurred in 8.3% of HyQ infusions compared to 25% of infusions in the IV arm. HyQ also demonstrated improved bioavailability compared to IGSC and similar trough levels to IGIV when administered at 3 or 4-week intervals, at infusion rates and times faster than IGIV.  Baxter submitted regulatory applications in the US in the second quarter and in the EU in the third quarter.
  • Achieved a $3 million milestone under ViroPharma agreement triggered by ViroPharma's initiation of an open-label, multi-dose Phase 2 study of Cinryze
    '/>"/>

    • SOURCE Halozyme Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
    2. Halozyme Begins Clinical Trial with HTI-501 in Women with Edematous Fibrosclerotic Panniculopathy
    3. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
    4. Halozyme Therapeutics to Present Data on its Ultrafast Insulin Programs at the Upcoming American Diabetes Association 71st Scientific Sessions
    5. Halozyme Therapeutics to Present at the Jefferies 2011 Global Healthcare Conference on June 9
    6. Halozyme Therapeutics Reports First Quarter 2011 Financial Results
    7. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
    8. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
    9. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
    10. Halozyme Receives $5.5 Million Payment From Baxter
    11. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/23/2013)... 2013 Can economic incentives such as ... members of the public to increase their donations of ... Hopkins Carey Business School Assistant Professor Mario Macis ... a large body of recent research that supports their ... 2013, issue of Science that the World Health Organization ...
    (Date:5/23/2013)... Wis. , May 23, 2013 ... researcher, developer, and marketer of over-the-counter (OTC) medicinal ... its research opinion on the company based on ... , Non-Prescription, All Natural Product to ... the Product Outperforms #1 Prescription Competitor , ...
    (Date:5/23/2013)... PI’s new LPS-24 positioners are less ... travel range with closed-loop sensor resolution up to ... new positioners the ideal choice for high precision ... is also available. , More Information: Specifications ... found at: , http://www.physikinstrumente.com/en/products/prdetail.php?sortnr=1000745&prw-lps24 , Reference-Class ...
    (Date:5/23/2013)... MENLO PARK, Calif. , May 23, 2013 /PRNewswire/ ... an oral treatment for pain has reached an important ... clinical trial of VBY-036 - a selective cathepsin S ... of VBY-036 is a double-blind, randomized, placebo-controlled study designed ... escalating doses of VBY-036 in healthy adults. ...
    Breaking Biology Technology:Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 3PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3
    ... Vascular,Inc. (Nasdaq: LMAT ) (the "Company") today announced ... of Directors, effective as of January 1,2008. Mr. Hays ... election at,the next annual meeting of the Company,s shareholders, ... and Corporate Governance Committee and,as a member of its ...
    ... Pilot Chevrolet Car, VALLEY FORGE, Pa., Dec. 17 ... joined with Diversified Racing Solutions,(DRS) to enter the NASCAR(R) ... the NASCAR Sprint Cup Series in 2010. In the ... the flagship,sponsor; the venture will be primarily funded by ...
    ... Holding, Inc. (Other OTC: NHGI) today announced that ... are,posted on the OTCIQ, a service of the ... portal that provides issuers access to,innovative products and ... mitigate risk, gather market,intelligence, and inspire better corporate ...
    Cached Biology Technology:LeMaitre Vascular Appoints Russell D. Hays to Its Board of Directors 2Good Neighbor Pharmacy Joins with Diversified Racing Solutions to Enter NASCAR Nationwide Series in 2008 2National Stem Cell Holding, Inc. Posts Company and Financial Information on the OTCIQ and Has Retained New CFO and Counsel to File Registration Statement With SEC 2
    (Date:5/23/2013)... suppresses lipid synthesis in the liver, UC Irvine endocrinologists ... liver diseases. , With this finding, Dr. Ellis ... in the field. Study results appear in the May ... , "The dogma in the steroid receptor field for ... the nucleus respond to steroid hormones by regulating genes ...
    (Date:5/23/2013)... succeeded in treating cerebral palsy with autologous cord blood. ... 2.5 year old boy had been in a persistent ... two months after treatment with the cord blood containing ... months, the child learned to speak simple sentences and ... Korean study, dispel the long-held doubts about the effectiveness ...
    (Date:5/22/2013)... U.S. Forest Service scientists are part of "Landscapes ... the TKF Foundation, will examine how collaborative planning and ... from tragedy. , The TKF Foundation announced today that ... for grant funding. In addition to research on the ... and resiliency, the 3-year, $585,000 grant will contribute to ...
    Breaking Biology News(10 mins):UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2First successful treatment of pediatric cerebral palsy with autologous cord blood 2'Landscapes of Resilience' to study how people use nature as a source of recovery 2
    ... RIDGE, Tenn., June 15, 2011 A first of ... Department of Energy,s Oak Ridge National Laboratory is providing ... biofuels. , Lignin, a major component of plant cell ... the production of cellulosic ethanol. The exact shape and ...
    ... A long-term study verifies multi-paddock grazing improves ... continuous grazing in large-scale ranches, according to Texas ... impacts on vegetation and soils achieved by commercial ... to changing circumstances to achieve desirable outcomes, said ...
    ... International and American Associations for Dental Research (IADR/AADR) have ... and Pulp Regeneration," held in Geneva, Switzerland, July 2010. ... and Regeneration Group, and they are published in volume ... an E-supplement to the Journal of Dental Research ...
    Cached Biology News:ORNL neutrons, simulations reveal details of bioenergy barrier 2AgriLife research: Multi-paddock grazing is superior to continuous grazing 2AgriLife research: Multi-paddock grazing is superior to continuous grazing 3AgriLife research: Multi-paddock grazing is superior to continuous grazing 4IADR/AADR publish proceedings from Symposium on Tissue Injury and Pulp Regeneration 2
    ...
    ...
    ... Experion software, PC, is used to ... data obtained from the Experion automated ... in electropherogram and simulated gel views ... calculations in a Results table. This ...
    ... for use in the Microsart e.motion are sterile-sealed, ... in a specially designed individual package on a ... band of membrane filter units ensures that they ... the sealed band guarantees uniform dispensing of the ...
    Biology Products: